ReNAgade Therapeutics
RNA Without Limits
RNA Without Limits
ReNAgade Therapeutics is a biotechnology startup founded in 2021 with a clear vision encapsulated in its slogan "RNA Without Limits." It aims to leverage the potential of RNA medicines to target diseases across the entire human body. By integrating innovative RNA delivery platforms with a comprehensive RNA system for coding, editing, and gene insertion, ReNAgade is committed to developing groundbreaking medicines. Its recent milestone was marked by a substantial $300.00M Series A investment on 23 May 2023, led by MPM Capital and F2 Ventures. Based in the United States, the company has assembled a team with profound expertise in RNA and delivery, steering the way forward for transformative RNA therapeutics. ReNAgade Therapeutics holds the promise of reshaping the future of medicine with its boundless approach to RNA.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $300.00M | 2 |
|
23 May 2023 |
No recent news or press coverage available for ReNAgade Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
